Jerome Siegel (University of California, Los Angeles, CA, USA) discusses sleep research in hunter-gatherer populations and what we can learn from the sleep habits of various species; his Review is published in the October issue of The Lancet Neurology, which is the fourth paper in The Lancet’s Series on sleep and sleep disorders.

Laurent Servais and Dora Markati (both from the University of Oxford, UK) discuss emerging therapies for Duchenne muscular dystrophy; their Review is published in the September issue of The Lancet Neurology.

Andreas Charidimou (Massachusetts General Hospital, Boston, MA, USA) discusses an international collaborative study that presents new Boston criteria for diagnosis of cerebral amyloid angiopathy; the Article is published in the August issue of The Lancet Neurology.

Sarah Tabrizi (UCL Queen Square Institute of Neurology, London, UK) and Cristina Sampaio (CHDI Foundation, Princeton, NJ, USA) discuss two papers on Huntington’s disease published in the July issue of The Lancet Neurology: a Position Paper outlining a new classification of the disease, called the Huntington’s Disease Integrated Staging System, and a Personal View on potential disease-modifying therapies.

Mark Hallett (National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA) discusses his Review, published in the June issue of The Lancet Neurology, on functional neurological disorder, and talks about new subtypes of this disorder, diagnostic challenges, and how education is important.

Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology, on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology.